China approves domestic Ebola vaccine developed from recent outbreak

China has approved a domestically developed Ebola vaccine based on a different virus type from GSK's and Merck's shots. (CanSino)

As promising Ebola vaccines from global drugmakers GlaxoSmithKline and Merck & Co. still await official licenses, China has approved its own shot, co-developed by the Chinese Academy of Military Medical Sciences’ Bioengineering Institute and domestic vaccine specialist Tianjin CanSino Biologics.

Dubbed Ad5-EBOV, the recombinant adenovirus vector-based vaccine is the first shot based on the strain behind the recent epidemic in West Africa in 2014—the deadliest outbreak in recorded history. Along with the CFDA decision, the Chinese vaccinemaker revealed (Chinese) a 65,000-square-meter (700,000-square-foot), 70-million-dose-capacity manufacturing site, which the company said is in compliance with the World Health Organization’s cGMP requirement.

The vaccine differs from programs at GSK and Merck because those companies' vaccines are developed to express the glycoprotein of the Ebola virus identified during the disease’s discovery back in 1976. CanSino says the two virus types are very similar, but slight differences could allow its shot to provide better protection in the real world.

Whitepaper

Developing COVID-19 vaccines may not be enough: Turning vaccines into vaccinations

COVID-19 vaccines are being developed at a breakneck pace, but a broken supply chain could derail that momentum. What are the steps needed to help ensure the medical supply chain is up to the task?

RELATED: Ebola vaccines from GlaxoSmithKline, Merck elicit yearlong response, study finds

Because the Ebola crisis has died down, China’s FDA approved Ad5-EBOV without a phase 3 test after putting the product on its expedited review list in April. CanSino told FiercePharma that the vaccine has also been through a challenge experiment at the microbiology lab at the Public Health Agency of Canada, the original developer of Merck's rVSV-ZEBOV.

In a 500-participant phase 2 trial in Sierra Leone, the results of which were published earlier this year in The Lancet, the vaccine elicited strong antibody responses in volunteers within 28 days. Researchers noted that the responses, though still existent, decreased significantly at day 168, a finding the team said is consistent with previous tests on rVSV-ZEBOV in Africa and Europe.

In a related commentary published alongside the Ad5-EBOV study results, two experts from the Netherlands expressed concerns about the “durability of protection when implementing mass vaccination campaigns in future outbreak settings in Africa.” CanSino, in a written response to FiercePharma, said the product is positioned for emergency use for now; therefore, it's currently not focused on long-term efficacy. The company didn't rule out the possibility for implementing a booster shot in the future.

RELATED: Sinovac to go private as bribery concerns hint at investor class-action lawsuits

A recent phase 2 study conducted by a U.S.-Liberia partnership showed that responses to Merck’s and GSK’s shots also peaked after a month, and that most recipients of the two shots still had an antibody response at one year.

CanSino's program further incorporates a freeze-drying technique known as lyophilization, which allows the vaccine to be stored at 4°C (39°F) for a long time, and to remain stable at 37°C (99°F) for about three weeks. The other two candidates, on the other hand, must be stored at -70°C (-94°F) or below, and are stable for only one week at 4°C (39°F). This means CanSino's version could be more suitable for the African region in terms of logistics.

Suggested Articles

The lawsuit is part of a years-long battle between the Cochrane Collaboration and Roche around Tamiflu's use against pandemic influenza.

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.